Study investigates the receptor affinity and antigenicity of the SARS-CoV-2 Omicron BA.2.86 variant, revealing that it does not show higher resistance to neutralization by human sera than other recent variants. Despite its high number of mutations and receptor affinity, the variant is slightly more sensitive to neutralization than the EG.5.1 variant, warranting continued surveillance.
CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growth – Biotech Investments
EQS-News: Cheplapharm AG / Key word(s): Annual Results/Annual Report CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growth 26.04.2024 / 11:55 CET/CEST The